Document is current
Any future updates will be listed below
-
Authors
Cruz, Víctor L.
Duro-Sánchez, Jorge
Franco-Mateos, Emma
García-Estévez, Laura
Pérez-García, José
Gion, María
Garrigós, Laia
Cortez, Patricia
Saavedra, Cristina
Gómez, Patricia
Ortiz, Carolina
Aguinagalde, Arantxa
Ramos, Javier
Cortés, Javier
Vega, Juan F.
-
Funding
Funding for this research was provided by:
Consejo Superior de Investigaciones Científicas (PIE202250E035; PIE202350E113, PIE202250E035; PIE202350E113, PIE202250E035; PIE202350E113, PIE202250E035; PIE202350E113, PIE202250E035; PIE202350E113)
Fundación “Contigo contra el cáncer de la mujer”.
Fundación FERO
- License Information
-
More Information
Article History
Received: 6 November 2024
Accepted: 28 July 2025
First Online: 6 August 2025
Declarations
:
: J.C. Consulting/Advisor: Roche, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Lilly, Merck Sharp&Dohme, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics, Scorpion Therapeutics, Expres2ion Biotechnologies, Jazz Pharmaceuticals, Abbvie, BridgeBio, Biontech, Biocon, Circle Pharma. Honoraria: Roche, Novartis, Eisai, Pfizer, Lilly, Merck Sharp&Dohme, Daiichi Sankyo, Astrazeneca, Gilead, Steamline Therapeutics. Research funding to the Institution: Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F. Hoffman-La Roche, Guardanth Health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Iqvia, Queen Mary University of London. Stock: MAJ3 Capital, Leuko (relative). Travel, accommodation, expenses: Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo, Astrazeneca, Gilead, Merck Sharp&Dhome, Steamline Therapeutics. Patents: (i) Pharmaceutical Combinations of A Pi3k Inhibitor and A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A. ISSUED, (ii) HER2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy. Aleix Prat, Antonio Llombart, Javier Cortés. US 2019/ 0338368 A1. LICENSED. J.P.-G. Advisory Role: Lilly, Roche, Eisai, Daichii Sankyo, AstraZeneca, Seattle Genetics, Gilead, MSD. Travel expenses: Roche. M.G. Honoraria: Novartis, Gilead, AstraZeneca, Pfizer. Travel grants, accommodation: Roche, Pfizer, AstraZeneca, Gilead. Advisory role: Gilead, Novartis, AstraZeneca. C.S. Speaker bureau: AstraZeneca, Daiichi Sankyo. Travel/accommodation/expenses: Pfizer, Astrazeneca, Novartis, Lilly. L.G.-E. Consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Gilead, Merck Sharp&Dhome, Lilly, Roche. Research funding to the institution: Roche. L.G. Speaker bureau: Novartis, Daiichi Sankyo. The other authors declare no competing interests.
